Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7796380 | 1.00 | LMNA (0.38) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL7563577 | 1.00 | LMNA (0.38) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL22032019 | 0.97 | LMNA (0.33) | LMNA | |
| SCHEMBL11421524 | 0.94 | LMNA (0.42) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL17111382 | 0.94 | LMNA (0.42) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL195985 | 0.94 | LMNA (0.42) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL78572 | 0.94 | LMNA (0.42) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL14717610 | 0.94 | LMNA (0.42) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL480135 | 0.94 | LMNA (0.42) | LMNACA1CA2MMP1MMP2 | |
| SCHEMBL36219 | 0.90 | LMNA (0.37) | LMNACA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4285928-A | AN EMULSION OF AN X-RAY CONTRAST AGENT AND A MIXTURE OF PERFLUORO COMPOUNDS HAVING OXYGEN-CARRYING ABILITIES | Wada, Juro (JP) | 1981-08-25 | — | — | US | claimed |
| US-20020164379-A1 | Oxygen-containing ophthalmic composition | ROHTO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-5262442-A | Fluosol for injection for oxygen transport | ALPHA THERAPEUTIC CORPORATION (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0548601-A1 | Process for rapid thawing and storage of frozen fluorocarbon emulsion, and resultant product | ALPHA THERAPEUTIC CORPORATION (US) | 1993-06-30 | — | — | EP | disclosed |
| US-4285928-A | AN EMULSION OF AN X-RAY CONTRAST AGENT AND A MIXTURE OF PERFLUORO COMPOUNDS HAVING OXYGEN-CARRYING ABILITIES | Wada, Juro (JP) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164379-A1 | Oxygen-containing ophthalmic composition | OGFOD1, HIF1A, HAO2 | LMNA 3995/4885CA1 2962/4885CA2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.